Navigation Links
Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor
Date:11/11/2009

CAMBRIDGE, MA November 11, 2009 Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival. This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. There are estimated to be more than 1,500 transcription factors in the human genome, regulating key biological processes important in diseases such as arthritis, asthma, diabetes, infectious diseases, and cancer .

In their research published in Nature, Drs. Bradner and Verdine showed in multiple models, including T-cell acute lymphoblastic leukemia (T-ALL), that Stapled Peptides achieved tight direct binding to the Notch transcription factor complex, preventing the assembly of a functional transcription complex by the Notch1 oncogene. Further in vivo data show that direct and specific antagonism of the Notch multi-protein complex in the nucleus of cancer cells suppressed the transcription of many growth stimulating proteins such as Myc, thereby leading to cancer cell death. Potent, specific pathway inhibition was determined using genome-wide transcriptional signatures, first in vitro and later validated as biomarker studies in vivo. The direct inhibition achieved did not result in gastrointestinal toxicity, suggesting a viable therapeutic window for Stapled Peptides, without the limitations previously observed with upstream inhibitors of Notch.

"Transcription factors are among the most desirable and validated therapeutic targets in cancer, yet they are among the most elusive targets in cancer drug discovery," said James Bradner, MD,, Division Of Hematologic Neoplasia, Dana-Farber Cancer Institute. "Our research shows, for the first time, how assembly of the Notch multi-protein transcription factor complex can be inhibited in the nucleus of a cancer cell with a stapled peptide, leading to cancer cell death. Using stapled peptides to target transcription factors opens a potential new path for discovering novel and effective therapies for patients."

A growing body of research describes the critical role that transcription factors play in biological pathways implicated in a broad array of human diseases. In the past 25 years, for example, the 20 most-cited transcription factors have been referenced in the scientific literature an estimated 100,000 timesi. In cancer biology, it has been shown that more than 50% of T-cell acute lymphoblastic leukemias (T-ALL) have activating mutations in Notch . However, the vast majority of transcription factors lack an appropriate binding pocket for targeting by small molecules. Moreover, most transcription factors reside within cells and so are not suitable for antibody-based therapies. Stapled Peptides have now been shown to inhibit a previously-undruggable transcription factor at a therapeutically meaningful level.

"These results are tantamount to a declaration of open season on transcription factors," said Gregory L. Verdine, PhD, Erving Professor of Chemistry, Harvard University and co-chair of Aileron Therapeutics' scientific advisory board. "While the vast majority of transcription factors are not druggable with current small molecule or biologic modalities, many features of the protein-protein interaction represented by Notch are similar to other transcription factor assemblies, giving us good reason to expect that this technology will be useful for other currently undruggable targets across diseases such as cancer, inflammation, obesity, and infection."

"The publication of a second major research article in Nature within a year demonstrates the momentum and potential for development of Stapled Peptides as a new drug modality," said Joseph Yanchik, III, Chief Executive Officer of Aileron Therapeutics. "Stapled Peptides designed to target important biologic but previously undruggable transcription factors, such as Notch, is a major focus of Aileron's R&D effort and is of significant interest as one of our potential early clinical development programs."

In a study published in Nature in October 2008 titled "BAX Activation is Initiated at a Novel Interaction Site," Aileron Therapeutics collaborators at the Dana Farber Cancer Institute demonstrated that a Stapled Peptide was able to uniquely target a new and fundamental activation mechanism of the programmed cell death or "apoptotic" pathway.

Aileron has developed Stapled Peptides designed to target specific transcription factors across multiple therapeutic areas, and is advancing these compounds in its preclinical programs.


'/>"/>

Contact: Kathryn Morris
kathryn@kmorrispr.com
845-635-9828
Yates Public Relations
Source:Eurekalert

Related medicine news :

1. Old Colony Elder Services Collaborates with The Charity Guild of Brockton to Offer "Special Foods for Special People" Program
2. UNTHSC Collaborates With Law Enforcement to Provide Alternatives to Dallas Prostitutes
3. WellPoint Collaborates with RedBrick Health to Create Integrated, Behavior-Based Wellness and Incentives Programs
4. Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency, Expand Access to Health Care Cost Information
5. Partnership Collaborates on HIE for Interoperability of Electronic Health Records and Patient Data in Ohio
6. Michigan State Medical Society Collaborates With Microsoft to Expand Health Care Technology in Michigan
7. Apollo Health Street Collaborates with Client to Develop a CCHIT-Certified 08 Ambulatory EMR
8. HealthCentral.com Collaborates With BreastCancer.org, Providing Quality Awareness Sponsorships to #1 Breast Cancer Resource Online
9. Impac Software Collaborates With the National Comprehensive Cancer Network to Improve Patient Care
10. Healthbase Collaborates with WellPoint to Bring Affordable Medical Tourism Solutions
11. Pathwork Diagnostics Collaborates With Guys and St Thomas on Tissue of Origin Test Validation in the UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for ... Care Association of America (HCAOA). This agreement allows HCAOA members to receive special ... as discounts on Accreditation University (AU) educational resources that help prepare HCAOA members ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Horizon Blue Cross ... the company’s credit rating of “A” and its outlook as “stable.” At the same ... reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required for ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program ... delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in ... and decide to donate. , “Women’s Hospital at Renaissance has been a collection ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain ... After Tina Howe joined the team, the Bill Howe brand was born and they ... rates, and giving back to the San Diego community in which they worked, lived ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: